The Infection That Won’t Quit

Anyone who has experienced chronic Lyme disease knows the pattern. The acute infection is treated — sometimes with antibiotics, sometimes with frequencies — and the spirochetes appear to be addressed. But the fatigue persists. The sinus problems linger. The brain fog refuses to lift. The flu-like symptoms cycle endlessly.

The reason, in many cases, is mycoplasma.

Mycoplasma co-infections are among the most underdiagnosed and undertreated components of the Lyme disease complex. They are the primary reason why many people with Lyme continue to feel sick long after the Borrelia spirochetes have been addressed. Understanding and eliminating mycoplasma is essential for anyone dealing with chronic Lyme and its cascading effects on long-term health — including cognitive decline and neurodegeneration.

What Are Mycoplasma?

Mycoplasma are the smallest known free-living organisms — sitting at the boundary between bacteria and viruses in terms of size and complexity. They are unique among bacteria for one critical reason: they lack a cell wall. This single characteristic makes them exceptionally difficult to treat and extraordinarily persistent.

Why the Lack of a Cell Wall Matters

Most antibiotics, including penicillin and its derivatives, work by attacking bacterial cell walls. Since mycoplasma have no cell wall, these antibiotics are completely ineffective against them. This means that standard Lyme disease antibiotic protocols, which target the cell-walled Borrelia spirochetes, do nothing to address mycoplasma co-infections. The spirochetes may be eliminated while the mycoplasma remain untouched — continuing to cause symptoms that are attributed to “post-treatment Lyme disease syndrome” when they are actually an ongoing, unaddressed infection.

How Mycoplasma Cause Chronic Symptoms

Mycoplasma are parasitic organisms that attach to and invade human cells, living off the host cell’s nutrients and energy resources. They commonly attach to red blood cells, siphoning energy and reducing oxygen delivery throughout the body. This is visible under dark-field microscopy as small spherical forms attached to red blood cells — a hallmark observation that the Frequency Research Foundation has documented extensively.

The energy depletion caused by mycoplasma attachment to red blood cells explains many of the persistent symptoms of chronic Lyme: the crushing fatigue, the excessive need for sleep, the inability to recover normal energy levels despite treatment of the primary spirochete infection.

Mycoplasma also trigger chronic immune activation. The immune system recognizes the mycoplasma as foreign but cannot effectively eliminate them due to their ability to invade cells and modify their surface proteins. This creates a perpetual inflammatory state — the body fighting an infection it cannot resolve — which produces the ongoing flu-like symptoms, joint pain, and malaise characteristic of chronic Lyme.

Mycoplasma in the Lyme Disease Complex

Lyme disease is rarely a single-organism infection. The ticks that transmit Borrelia burgdorferi (the Lyme spirochete) frequently carry multiple co-infections, and the resulting illness is more accurately described as a complex of interacting organisms.

The Key Players

The Lyme disease complex typically involves Borrelia spirochetes as the primary infection, which produce the most immediately disabling neurological and joint symptoms. Mycoplasma species, particularly Mycoplasma fermentans, serve as persistent co-infections that drive chronic fatigue and immune dysfunction. Various viruses contribute to immune suppression and neurological symptoms. Fungal organisms create additional immune burden. The interactions between these organisms are synergistic — each one makes the others more difficult to eliminate and more damaging to the host.

Why Addressing Spirochetes Alone Is Not Enough

Most conventional Lyme disease treatment focuses exclusively on eliminating Borrelia spirochetes with antibiotics. As Dr. Jeff Sutherland has observed in clinical practice, the spirochetes can be addressed relatively quickly with targeted frequencies — often in a matter of hours. However, the more difficult organisms are the viruses, the fungi, and above all the mycoplasma.

The mycoplasma are particularly challenging because they are often infected with nanobacteria — organisms within organisms. Eliminating mycoplasma therefore triggers a nanobacteria Herxheimer reaction as the secondary organisms are released. The primary symptom of nanobacteria infection is the need for excessive amounts of sleep, which is commonly seen in people with chronic Lyme infections and is often mistakenly attributed to the Lyme itself rather than to the co-infection within the co-infection.

This layered complexity is why a systematic approach is essential. At the Frequency Research Foundation, Dr. Jeff Sutherland’s research has focused on systematically disassembling mycoplasma with frequencies that target various parts of the organism and disperse the DNA. There are multiple mycoplasma strains in the Lyme complex, and untangling them all is a nontrivial task that requires careful, sequential treatment.

The Scale of the Problem

The prevalence of pathogenic mycoplasma in the general population is far greater than most people realize. Of the approximately 200 known species of mycoplasma, most are innocuous. However, four or five species are pathogenic to humans, and these have become increasingly widespread.

Widespread Infection

Research from multiple sources suggests that pathogenic mycoplasma now infect a significant portion of the population. Dr. Shyh-Ching Lo, a senior researcher at the Armed Forces Institute of Pathology and one of America’s leading mycoplasma researchers, has documented the connection between Mycoplasma fermentans and numerous chronic diseases. Dr. Lo holds a patent on Mycoplasma fermentans extracted from AIDS patients, and his research links this organism to chronic fatigue syndrome, fibromyalgia, and multiple other conditions.

Dr. Charles Engel of the US National Institutes of Health stated at an NIH meeting on February 7, 2000: “I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma.”

According to Dr. Lo’s research, pathogenic mycoplasma have been implicated in AIDS, cancer, chronic fatigue syndrome, Crohn’s colitis, type 1 diabetes, multiple sclerosis, Parkinson’s disease, Wegener’s disease, collagen-vascular diseases such as rheumatoid arthritis, and Alzheimer’s disease.

The Frequency Research Foundation’s Clinical Experience

The Frequency Research Foundation has been identifying and developing frequencies for pathogenic mycoplasma since 2001. In over two decades of clinical observation, we have consistently found mycoplasma infections in a high percentage of chronically ill individuals — particularly those presenting with persistent Lyme disease, chronic fatigue, unexplained cognitive decline, and treatment-resistant cases.

Our companion articles cover additional dimensions of the mycoplasma problem: Mycoplasma Pneumoniae and Other Mycoplasmas provides an overview of the various species and their systemic effects, while Mycoplasma: A Key Component in Lyme and Other Diseases examines mycoplasma’s role as the critical co-infection that complicates recovery from Lyme and other chronic conditions.

Mycoplasma and the Brain: The Alzheimer’s Connection

The connection between mycoplasma and neurodegenerative disease is directly relevant to our Alzheimer’s research.

How Mycoplasma Damage the Brain

Mycoplasma can cross the blood-brain barrier — a critical distinction that separates them from many other pathogens. Once inside the brain, they trigger chronic microglial activation and neuroinflammation. This is the same persistent inflammatory state that drives Alzheimer’s disease progression.

The brain damage from mycoplasma operates through several mechanisms. Direct neuroinflammation from the immune system’s chronic attempt to fight an infection it cannot clear. Energy depletion of neurons through parasitic attachment. Disruption of neurotransmitter metabolism. Promotion of oxidative stress that damages neuronal membranes and DNA.

This means that for some people, chronic mycoplasma infection may be a contributing factor — or even a primary driver — of cognitive decline and neurodegenerative disease. Eliminating mycoplasma is therefore not just a Lyme disease issue. It is a brain health issue.

Our complete guide to Alzheimer’s disease and frequency therapy covers the full range of infections linked to Alzheimer’s, including not only mycoplasma but also herpes simplex virus — which has been found in 90% of Alzheimer’s plaques, as documented in our article Alzheimer’s and Herpes Simplex Virus.

2026 Update: What Has Advanced Since 2008

Since this article was first published, several important developments have occurred in mycoplasma research and treatment.

Improved Detection Methods

Mycoplasma detection has improved significantly. Advanced PCR-based testing can now identify multiple mycoplasma species with greater sensitivity than was available in 2008. This has led to increased recognition of mycoplasma’s role in chronic illness, though mainstream medicine still underdiagnoses these infections dramatically.

The Chronic Infection-Neurodegeneration Link Is Established

What was still emerging in 2008 is now well-established: chronic infections, including mycoplasma, are recognized contributors to neurodegeneration and cognitive decline. The broader “infectious theory of Alzheimer’s” has gained significant scientific support, with multiple pathogen types — viruses, bacteria, and mycoplasma — all implicated in driving the neuroinflammatory cascade that produces Alzheimer’s pathology.

Frequency Protocol Advancement

The Frequency Research Foundation’s mycoplasma frequency protocols have been significantly refined since 2008. Dr. Jeff Sutherland’s systematic approach to disassembling mycoplasma — targeting various structural components and dispersing DNA — has been developed through years of iterative testing and clinical observation. The protocols now address a wider range of mycoplasma strains and account for the co-infections (including nanobacteria) that complicate treatment.

Our [Lyme disease frequency protocol, Version 11.0](INSERT LYME V11 URL) represents the latest evolution of our comprehensive approach to the Lyme complex, including its mycoplasma components.

Post-COVID Relevance

The COVID-19 pandemic created millions of people with persistent symptoms — long COVID — that closely mirror chronic Lyme and mycoplasma infection: fatigue, brain fog, immune dysfunction, and chronic inflammation. This has brought mainstream attention to the concept of post-infectious chronic illness and has made the medical community more receptive to the idea that persistent organisms can drive ongoing symptoms long after the initial infection.

How Frequency Therapy Addresses Mycoplasma

Mycoplasma’s lack of a cell wall, which makes it resistant to most antibiotics, does not protect it from electromagnetic frequencies. Frequency therapy offers a fundamentally different mechanism of action that bypasses the cell wall entirely.

The Frequency Approach to Mycoplasma

Dr. Jeff Sutherland’s approach to mycoplasma involves a systematic, multi-stage process. Targeted frequencies address the mycoplasma organism directly, disrupting its structural integrity despite the absence of a cell wall. Sequential treatment addresses the nanobacteria that mycoplasma harbor internally, managing the Herxheimer reactions that occur as these secondary organisms are released. Strain-specific frequencies address the multiple mycoplasma species present in the Lyme complex. Supporting frequencies address the immune dysfunction and energy depletion that mycoplasma cause.

This systematic approach is necessary because mycoplasma infections are not simple, single-organism problems. They involve multiple strains, internal co-infections, and layered immune dysfunction that must be addressed in the right sequence.

Why Frequency Therapy Has an Advantage

Conventional antibiotics that work against mycoplasma — primarily tetracyclines and macrolides — require long treatment courses (often months), come with significant side effects, and have incomplete efficacy because mycoplasma can hide inside host cells where antibiotic concentrations may be subtherapeutic.

Frequency therapy is not limited by cell wall targeting, does not require months-long courses, can address organisms inside host cells, and can target multiple strains and co-infections within the same treatment framework.

Dealing with chronic Lyme, persistent fatigue, or unexplained cognitive symptoms? Mycoplasma co-infections may be the missing piece. Dr. Jeff Sutherland offers personalized paid consultations to identify the specific organisms driving your symptoms and develop a targeted frequency protocol. Book Your Consultation

Frequently Asked Questions

Take the Next Step

If you have been dealing with chronic Lyme disease, persistent fatigue, ongoing sinus problems, or unexplained cognitive decline, mycoplasma co-infections may be the underlying reason your symptoms continue despite treatment.

Dr. Jeff Sutherland has spent over two decades developing frequency protocols specifically for mycoplasma and the complex infections that accompany them. A paid consultation is the most direct way to assess whether mycoplasma is a factor in your case and develop a targeted treatment plan.

Book Your Consultation with Dr. Jeff Sutherland

This article is part of our comprehensive Alzheimer’s resource library. Mycoplasma infections that cross the blood-brain barrier contribute to the neuroinflammation that drives Alzheimer’s disease. Read our complete guide to Alzheimer’s disease and frequency therapy for the full scope of research on infections, environmental toxins, nutrition, and frequency-based treatment approaches.

© Frequency Research Foundation. This content is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult with qualified healthcare professionals regarding medical conditions.

The Organism Most Doctors Don’t Test For

If you have been dealing with chronic illness — whether it carries a diagnosis of Lyme disease, chronic fatigue syndrome, fibromyalgia, autoimmune disease, or unexplained cognitive decline — there is a significant probability that mycoplasma is involved. And there is an equally significant probability that no one has tested for it.

Mycoplasma are the smallest known self-replicating organisms. They are not quite bacteria, not quite viruses — they occupy a unique biological category that falls between conventional diagnostic boundaries. This in-between status is part of the reason they are so frequently missed. They do not grow on standard bacterial culture plates. They do not respond to the most commonly prescribed antibiotics. And they are not included in routine diagnostic panels for most of the diseases they contribute to.

At the Frequency Research Foundation, Dr. Jeff Sutherland has observed mycoplasma in over 80% of people tested — a finding consistent with other independent researchers in the field. Understanding mycoplasma is not a niche concern. It is central to understanding why so many chronic diseases persist despite treatment.

How Mycoplasma Work: The Cellular Mechanism

What makes mycoplasma uniquely dangerous is their method of survival. They are intracellular parasites — meaning they enter human cells and live inside them, using the cell’s own resources to survive and reproduce.

The Invasion Process

Mycoplasma enter individual cells and, depending on genetic predisposition, may target different tissues in different people. If the pathogen destroys cells in the brain, neurological disease may develop. If it invades and destroys cells in the lower bowel, conditions like Crohn’s colitis may follow. If it targets joint tissues, rheumatoid arthritis or other collagen-vascular diseases may result.

This tissue-specific targeting explains one of the most puzzling aspects of mycoplasma-related illness: why the same organism produces such different diseases in different people. The answer lies in individual genetic predisposition and which tissues the mycoplasma infiltrate.

The Dormancy Problem

One of mycoplasma’s most challenging characteristics is their ability to lie dormant inside cells for extended periods — potentially 10, 20, or even 30 years. During dormancy, they cause no symptoms and are virtually undetectable. They can be triggered into active infection by trauma, surgery, vaccination reactions, severe stress, immune suppression, or co-infection with other pathogens.

This dormancy-activation pattern explains many cases of sudden-onset chronic illness in previously healthy individuals. A triggering event activates dormant mycoplasma, which then begins destroying host cells and provoking immune responses that produce chronic symptoms.

How They Kill Cells

Because mycoplasma lack the organelles to process their own nutrients, they survive by uptaking pre-formed sterols (essential fats) from the host cell. They literally consume the cell from within. When the cell is depleted, it ruptures and its contents — including inflammatory debris and mycoplasma progeny — are dumped into the bloodstream. This triggers immune activation and inflammation, while the released mycoplasma invade new cells and repeat the cycle.

This mechanism explains the fluctuating, relapsing-remitting symptom pattern that is characteristic of mycoplasma-related illness. Periods of relative calm alternate with flare-ups as cycles of cellular invasion, destruction, and immune response repeat.

Mycoplasma and the Lyme Disease Complex

The Frequency Research Foundation’s most extensive clinical experience with mycoplasma involves its role in Lyme disease. Mycoplasma is not a secondary or minor component of Lyme — it is a key factor driving chronic symptoms.

Clinical Observations

Dr. Jeff Sutherland’s clinical experience has revealed several consistent patterns. Mycoplasma fermentans is present in virtually all Lyme infections observed at the Foundation. When mycoplasma fermentans is targeted with frequencies, it produces what appear to be Brucella infections — both organisms must be targeted together along with several other pathogens for effective treatment.

Lyme infections are found in over 80% of the people Dr. Sutherland tests, a finding consistent with other researchers working in this area. The mycoplasma component is typically the most persistent element of the Lyme complex, outlasting spirochetes and most co-infections.

Why Mycoplasma Make Lyme Chronic

Standard Lyme treatment targets Borrelia spirochetes. Even when these are successfully eliminated, mycoplasma continue to cycle through invasion, dormancy, and reactivation — producing the fatigue, cognitive symptoms, and immune dysfunction that characterize “chronic Lyme.”

Our companion article Mycoplasma – Why the Lyme Flu Goes On and On examines this persistence pattern in detail, including the complicating role of nanobacteria within mycoplasma and the Herxheimer reactions that occur during treatment. For our latest comprehensive Lyme treatment protocol, see Update: Lyme Frequencies Version 11.0.

The Disease Associations: Far Beyond Lyme

Research from multiple independent investigators has linked pathogenic mycoplasma to a remarkably wide range of chronic diseases. This is not speculative — it is documented by senior researchers at major institutions.

Key Research Citations

Dr. Shyh-Ching Lo, a senior researcher at the Armed Forces Institute of Pathology and one of America’s leading mycoplasma researchers, has documented Mycoplasma fermentans in patients with AIDS, cancer, chronic fatigue syndrome, Crohn’s colitis, type 1 diabetes, multiple sclerosis, Parkinson’s disease, Wegener’s disease, collagen-vascular diseases including rheumatoid arthritis, and Alzheimer’s disease. Dr. Lo holds a US patent on Mycoplasma fermentans isolated from patients.

Dr. Charles Engel of the US National Institutes of Health stated at an NIH meeting on February 7, 2000: “I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma.”

Dr. Maurice Hilleman, who served as chief virologist for the pharmaceutical company Merck Sharp & Dohme, stated that this disease agent is now carried by the vast majority of people in North America and potentially most people worldwide.

The Common Thread

The common thread across all these diseases is chronic immune activation and inflammation driven by an intracellular pathogen that the immune system recognizes but cannot effectively eliminate. Different tissues are affected in different people, producing different diagnostic labels — but the underlying mechanism is the same.

This connects directly to our foundational article Eliminating Inflammation Is a Top Priority for Disease Prevention. Mycoplasma are one of the most important drivers of the chronic inflammation that underpins heart disease, cancer, neurodegenerative disease, and autoimmune conditions.

Mycoplasma and Alzheimer’s Disease

The neurodegenerative implications of mycoplasma infection deserve particular attention within our Alzheimer’s research.

The Brain Infiltration Pathway

Mycoplasma can cross the blood-brain barrier and establish infections within brain tissue. Once there, they trigger the same destructive cycle that occurs in other tissues — cell invasion, sterol depletion, cell rupture, inflammatory response — but in the brain, the consequences are devastating.

Chronic microglial activation in response to mycoplasma creates persistent neuroinflammation. Neuronal energy depletion from mycoplasma parasitism impairs cognitive function. The inflammatory debris from ruptured cells contributes to the toxic environment that promotes amyloid accumulation.

Mycoplasma as Part of the Infectious Theory of Alzheimer’s

Mycoplasma is one of several chronic infections now linked to Alzheimer’s disease. The broader pattern — documented in our complete guide to Alzheimer’s disease and frequency therapy — involves multiple pathogen types contributing to the neuroinflammatory cascade that produces Alzheimer’s pathology.

Herpes simplex virus DNA has been found in 90% of Alzheimer’s plaques, as documented in our article Alzheimer’s and Herpes Simplex Virus. Lyme spirochetes can directly invade brain tissue and trigger neuroinflammation. Mycoplasma add another layer of persistent, treatment-resistant infection that sustains the inflammatory environment.

For many Alzheimer’s patients, the disease may not have a single infectious cause but rather a combination of chronic infections — viral, bacterial, and mycoplasmal — each contributing to the neuroinflammatory burden. Addressing all of them is essential for a comprehensive treatment strategy.

Historical Context: The Origins of Pathogenic Mycoplasma

The question of how pathogenic mycoplasma became so widespread has been the subject of significant investigation. Researcher Donald W. Scott, MA, MSc, as president of the Common Cause Medical Research Foundation, compiled extensive documentation — drawing from US and Canadian government documents and peer-reviewed journals — suggesting that several mycoplasma strains were modified through biological warfare research programs dating from the 1940s onward.

According to Scott’s research, biological warfare programs in the United States, Canada, and Britain focused on weaponizing the Brucella bacterium, from which pathogenic mycoplasma were derived. Scott documented that these programs involved participation from the US Public Health Service, the CDC, and the NIH, and that the resulting organisms were tested on populations without informed consent.

These claims are supported by Scott’s collection of government documents, patents (including Dr. Lo’s US patent on Mycoplasma fermentans), and peer-reviewed publications from journals including the Journal of the American Medical Association, the New England Journal of Medicine, and the Canadian Medical Association Journal.

Whatever their precise origin, the clinical reality is that pathogenic mycoplasma are now ubiquitous and are contributing to chronic illness on a massive scale. Understanding how to detect and eliminate them is more immediately relevant than resolving the historical debate about their creation.

2026 Update: 20 Years of Advancement

Since this article was first published, understanding of mycoplasma’s role in chronic disease has advanced on multiple fronts.

Mainstream Recognition Is Growing

While mycoplasma remain underdiagnosed in conventional practice, the medical literature’s recognition of their role in chronic disease has expanded significantly. Mycoplasma are now acknowledged as potential contributors to a wider range of conditions than were recognized in 2005, and the mechanisms of intracellular parasitism and immune evasion are better understood.

The Microbiome Revolution

The explosion of microbiome research since 2005 has provided a broader framework for understanding how mycoplasma interact with other organisms in the body. Mycoplasma do not exist in isolation — they interact with the broader microbial ecosystem, and disruptions to the microbiome (from antibiotics, glyphosate, or other factors) can create conditions that favor mycoplasma proliferation.

Our article Glyphosate Alzheimer’s Disease: Could This Common Herbicide Increase Your Risk? covers how environmental toxins disrupt the microbial environment in ways that may favor pathogenic organisms like mycoplasma.

Frequency Protocol Refinement

The Frequency Research Foundation’s mycoplasma protocols have been refined extensively since 2005. Dr. Jeff Sutherland’s systematic approach now addresses a wider range of mycoplasma species and strains, accounts for the Brucella co-infections that emerge when mycoplasma fermentans is targeted, and manages the complex Herxheimer reactions that occur during treatment. The protocols are part of our comprehensive Lyme disease frequency protocol, Version 11.0.

Post-COVID Parallels

The COVID-19 pandemic created widespread awareness of post-infectious chronic illness. Long COVID symptoms — persistent fatigue, brain fog, immune dysfunction, chronic inflammation — closely mirror the symptom patterns of chronic mycoplasma infection. This parallel has made the medical community more receptive to the concept that organisms can persist after acute infection and drive chronic symptoms, opening doors for broader acceptance of mycoplasma’s role in chronic disease.

How Frequency Therapy Addresses Mycoplasma

Mycoplasma’s unique biology — no cell wall, intracellular residence, dormancy capability, multiple strains — demands an approach that conventional medicine is poorly equipped to provide. Frequency therapy offers distinct advantages for this particular organism.

Frequency Therapy’s Advantages Against Mycoplasma

Conventional antibiotics effective against mycoplasma (tetracyclines, macrolides, fluoroquinolones) face several limitations: they require months-long courses, they cannot reliably reach organisms inside host cells at therapeutic concentrations, and they cannot distinguish between mycoplasma strains.

Frequency therapy bypasses these limitations. Frequencies penetrate cell membranes and can reach intracellular organisms directly. Different frequencies can target different mycoplasma strains within the same treatment session. The approach can address the Brucella co-infections that emerge when Mycoplasma fermentans is disrupted. Nanobacteria within mycoplasma can be targeted as part of a sequential protocol.

The Clinical Approach

Dr. Jeff Sutherland’s approach to mycoplasma involves identifying which mycoplasma species and strains are present, targeting the mycoplasma and its associated Brucella component simultaneously, managing Herxheimer reactions through sequential treatment of internal co-infections, and supporting immune recovery as the infection burden is reduced.

This systematic, multi-organism approach reflects the clinical reality that mycoplasma infections are never simple, single-pathogen problems.

Chronic illness that won’t resolve? Mycoplasma may be the missing piece. Dr. Jeff Sutherland has over two decades of experience developing frequency protocols for mycoplasma and its co-infections. A paid consultation can identify whether mycoplasma is contributing to your symptoms and develop a targeted treatment plan. Book Your Consultation

Frequently Asked Questions

Take the Next Step

Mycoplasma is one of the most underdiagnosed and undertreated contributors to chronic illness worldwide. Whether your symptoms carry a label of Lyme disease, chronic fatigue, fibromyalgia, autoimmune disease, or cognitive decline, mycoplasma may be a key component driving the problem.

Dr. Jeff Sutherland has spent over 20 years developing frequency protocols specifically for mycoplasma and the complex co-infections that accompany them. A paid consultation is the most direct way to assess whether mycoplasma is a factor in your case.

Book Your Consultation with Dr. Jeff Sutherland

This article is part of our comprehensive Alzheimer’s resource library. Mycoplasma infections that infiltrate the brain contribute to the chronic neuroinflammation that drives Alzheimer’s progression. Read our complete guide to Alzheimer’s disease and frequency therapy for the full scope of research on infections, environmental toxins, nutritional strategies, and frequency-based treatment approaches.

© Frequency Research Foundation. This content is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult with qualified healthcare professionals regarding medical conditions.